Medical Oncology

The Department of Medical Oncology centers on pharmacologic therapy, focusing on systemic treatment for malignant tumors without relying on surgery or radiation. It employs chemotherapy, targeted therapies, immunotherapies, endocrine therapies, and other modalities to control tumor growth, serving as a key department in comprehensive, full‑cycle cancer management and working closely in collaboration with the departments of surgical oncology and radiation oncology. The department’s clinical scope encompasses all major types of malignancies, offering neoadjuvant therapy, adjuvant therapy following surgery, first‑line and later‑line systemic treatments for advanced disease, as well as palliative and symptomatic supportive care. Its primary therapeutic approaches include chemotherapy, targeted therapy, immunotherapy, endocrine therapy, and anti‑angiogenic therapy, while also managing both the tumor itself and the various complications and adverse effects associated with anticancer treatments.

For early- and mid-stage tumors, neoadjuvant drug therapy is administered to shrink the tumor burden and create favorable conditions for surgery; postoperative adjuvant therapy is then employed to eradicate occult micrometastases and reduce the risk of recurrence. For advanced malignancies with metastases, individualized treatment regimens are tailored based on genetic testing results to control disease progression, prolong survival, and improve patients’ quality of life. The department places great emphasis on managing toxicities and adverse effects during chemotherapy, targeted therapy, and immunotherapy, promptly preventing and treating bone marrow suppression, nausea and vomiting, hepatorenal dysfunction, and immune-related adverse events. At the same time, it provides comprehensive nutritional support and psychological counseling, while offering symptomatic management for cancer‑related pain, malignant pleural and peritoneal effusions, and other complications. Regular genetic testing and assessment enable timely adjustments to treatment plans, and a long-term follow-up system has been established. This approach is suitable for patients with a confirmed diagnosis of malignancy who require systemic pharmacologic anti‑tumor therapy, as well as those with advanced disease requiring comprehensive palliative care in an outpatient setting.